|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/395 | |
| A61P 7/06 | |||
| C07D 255/02 | |||
| A61K 45/06 | |||
| A61K 38/19 |
| (11) | Number of the document | 2709991 |
| (13) | Kind of document | T |
| (96) | European patent application number | 12786739.8 |
| Date of filing the European patent application | 2012-05-15 | |
| (97) | Date of publication of the European application | 2014-03-26 |
| (45) | Date of publication and mention of the grant of the patent | 2020-09-02 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2012/037970 |
| Date | 2012-05-15 |
| (87) | Number | WO 2012/158707 |
| Date | 2012-11-22 |
| (30) | Number | Date | Country code |
| 201161486632 P | 2011-05-16 | US |
| (72) |
DALE, David, C., US
BRIDGER, Gary, J., US
HSU, Frank, J., US
|
| (73) |
University of Washington,
Center for Commercialization 4311 11th Avenue NE, Suite 500, Seattle, WA 98105,
US
Genzyme Corporation, 50 Binney Street, Cambridge, MA 02142, US |
| (54) | Use of cxcr4 antagonists for treating WHIM syndrome, myelokathexis, neutropenia and lymphocytopenia |
| Use of cxcr4 antagonists for treating WHIM syndrome, myelokathexis, neutropenia and lymphocytopenia |